stockrow
Monday 9 November 2026
Export ALXO’s income statement to Excel — free account
ALX Oncology Holdings Inc.
ALXO- EPS
- +73.5%
- Free cash flow
- +31.7%
- Total debt
- −3.34%
Quarter to June 2026, against a year earlier
1.16
0.01
+0.87%
Follow ALXO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 2 | 5 | 1 | — | — | — | — | — | 2 | (24.4%) | — | — | — | — | |
| Gross margin, % | — | — | 9.05 | 9.09 | 9.05 | 0.00 | 0.00 | — | — | — | 0.00 | (9.0) pt | ||||||
| EBT | — | — | (14) | (19) | (45) | (83) | (123) | (161) | (135) | (102) | (81) | +33.2% | ||||||
| EBT margin, % | — | — | (662.12) | (400.52) | (3,849.32) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +662.1 pt | ||||||
| Net income | — | 0 | (14) | (19) | (46) | (83) | (123) | (161) | (135) | (102) | (81) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.75 | 1.56 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (6.33) | (7.56) | (2.76) | (2.07) | (3.03) | (3.74) | (2.58) | (1.90) | (1.13) | (15.8%) | ||||||
| Cash flow | — | — | (4.79) | (4.63) | (2.07) | (1.69) | (2.19) | (3.03) | (2.34) | (1.57) | (0.52) | (14.8%) | ||||||
| Capex | — | — | (0.24) | (0.11) | 0.00 | (0.12) | (0.04) | (0.03) | (0.01) | 0.00 | 0.00 | (44.2%) | ||||||
| Free cash flow | — | — | (5.03) | (4.75) | (2.07) | (1.81) | (2.23) | (3.06) | (2.35) | (1.57) | (0.52) | (15.3%) | ||||||
| Book value | — | — | 0.00 | (22.96) | 23.25 | 9.01 | 6.47 | 4.41 | 2.18 | 0.48 | 1.00 | n/m | ||||||
| Shares, m | — | — | 3 | 3 | 18 | 40 | 41 | 43 | 52 | 54 | 87 | +52.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | 25.44 | 25.44 | 653.57 | — | — | — | — | — | 64.54 | 234.8 | ||||||
| P/B | — | — | 0.00 | 0.00 | 3.71 | — | — | — | — | — | 1.16 | 1.2 | ||||||
| EV/Sales | — | — | 0.67 | 0.67 | 477.83 | — | — | — | — | — | 13.96 | 159.7 | ||||||
| EV/FCF | — | — | (0.12) | (0.12) | (30.40) | — | — | — | — | — | (0.48) | (10.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (13) | (14) | (38) | (68) | (89) | (130) | (122) | (84) | (71) | +30.3% | |||||
| Capex | — | — | (1) | 0 | 0 | (5) | (1) | (1) | 0 | 0 | 0 | (14.8%) | ||||||
| Free cash flow | — | — | (14) | (15) | (38) | (73) | (91) | (132) | (122) | (84) | (71) | +29.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 8 | 5 | 430 | 352 | 243 | 153 | 116 | 26 | 129 | +17.8% | |||||
| Net debt | — | — | (8) | (4) | (434) | (361) | (256) | (173) | (118) | (35) | (129) | +22.9% | ||||||
| Shareholders’ equity | — | — | — | (71) | 430 | 363 | 263 | 190 | 114 | 26 | 136 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | 0.00 | (435.95) | (22.81) | (20.45) | (35.97) | (58.58) | (69.10) | (98.34) | (63.16) | (98.3) pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (2,661.67) | (1,036.13) | (640.53) | 0.00 | 0.00 | (673.30) | 0.0 pt | ||||||
| ROE | — | — | 28.43 | 38.02 | (28.36) | (21.05) | (39.42) | (70.97) | (88.91) | (145.70) | (80.65) | (174.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 15 | 23 | 43 | 58 | 72 | 80 | 43 | — | +19.2% | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.32 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2020 · latest quarter Dec 2020 · fundamentals updated 26 Oct 2026
ALX Oncology Holdings Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PEPG PepGen, Inc. | $171.1M | — (loss-making) | — | — | n/m | +33.02% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CNTN Canton Strategic Holdings, Inc. | $164.1M | — (loss-making) | — | — | n/m | −600.39% (below 0%: shrinking) | 100.00% | (80.37%) | Compare |
| ZNTL Zentalis Pharmaceuticals, Inc. | $162.8M | — (loss-making) | — (loss-making) | — | n/m | −9.06% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IPHA Innate Pharma S.A. Sponsored ADR | $160.9M | — (loss-making) | — | +246.29% (above 0%: growing) | +106.08% (above 0%: growing) | −929.03% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ORMP Oramed Pharmaceuticals Inc. | $160.6M | 0.9× | 0.9× | +193.26% (above 0%: growing) | +493.75% (above 0%: growing) | +94.29% (above 0%: growing) | 0.65% | 0.00% | Compare |
| ALXO ALX Oncology Holdings Inc. | $159.7M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +31.65% (above 0%: growing) | 0.00% | 0.00% | |
| STRO Sutro Biopharma, Inc. | $159.5M | — (loss-making) | — (loss-making) | −84.57% (below 0%: shrinking) | n/m | +14.55% (above 0%: growing) | 100.00% | (303.77%) | Compare |
| ANTX AN2 Therapeutics, Inc. | $150.9M | — (loss-making) | — | — | n/m | +7.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| INO Inovio Pharmaceuticals, Inc. | $125.6M | — (loss-making) | — (loss-making) | −83.19% (below 0%: shrinking) | n/m | +13.41% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $160.7M | — | — | +55.04% | — | +10.66% | 50.33% | 0.00% |
Pay and ownership Proxy statement filed 20 April 2026
Ownership
Directors and executive officers, together
12.40%
Corey Goodman, Ph.D.
9.80%
RA Capital Management, L.P.
9.70%
Entities affiliated with TCG Crossover
9.70%
Entities affiliated with venBio Partners
9.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement